Poly(ADP-Ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets

Seminars in Radiation Oncology

Volumn 20, Issue 4, 2010, Pages 274-281

  Chalmers, Anthony J ^a   Lakshman, Mina ^b   Chan, Norman ^b   Bristow, Robert G ^b  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; AG 14361; E 7016; GPI 15427; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ATM GENE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; COLON CARCINOMA; ENZYME INHIBITION; GENE; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; LUNG CARCINOMA; NBS1 GENE; ONCOGENE; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; REVIEW; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

CLINICAL TRIALS AS TOPIC; DNA BREAKS, DOUBLE-STRANDED; DNA BREAKS, SINGLE-STRANDED; DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; ENZYME INHIBITORS; HUMANS; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; RADIATION ONCOLOGY; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION;

EID: 77956487620     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2010.06.001     Document Type: Review

References (55)

1. D'Amours D., Desnoyers S., D'Silva I., et al. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999, 342:249-268.
2. Ame J.C., Spenlehauer C., de Murcia G. The PARP superfamily. Bioessays 2004, 26:882-893.
3. Woon E.C., Threadgill M.D. Poly(ADP-ribose)polymerase inhibition-Where now?. Curr Med Chem 2005, 12:2373-2392.
4. Chalmers A.J. The potential role and application of PARP inhibitors in cancer treatment. Br Med Bull 2009, 89:23-40.
5. Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
6. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
7. Petermann E., Keil C., Oei S.L. Importance of poly(ADP-ribose) polymerases in the regulation of DNA-dependent processes. Cell Mol Life Sci 2005, 62:731-738.
8. O'Driscoll M., Jeggo P.A. The role of double-strand break repair-Insights from human genetics. Nat Rev Genet 2006, 7:45-54.
9. Caldecott K.W. Protein-protein interactions during mammalian DNA single-strand break repair. Biochem Soc Trans 2003, 31:247-251.
10. Dantzer F., de la Rubia G., Menissier-De Murcia J., et al. Base excision repair is impaired in mammalian cells lacking poly(ADP-ribose) polymerase-1. Biochemistry 2000, 39:7559-7569.
11. Horton J.K., Wilson S.H. Hypersensitivity phenotypes associated with genetic and synthetic inhibitor-induced base excision repair deficiency. DNA Repair (Amst) 2007, 6:530-543.
12. Noel G., Godon C., Fernet M., et al. Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol Cancer Ther 2006, 5:564-574.
13. Dungey F.A., Loser D.A. Chalmers: replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-ribose) polymerase: Mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 2008, 72:1188-1197. AJM.
14. Godon C., Cordelieres F.P., Biard D., et al. PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility. Nucleic Acids Res 2008, 36:4454-4464.
15. Kastan M.B., Bartek J. Cell-cycle checkpoints and cancer. Nature 2004, 432:316-323.
16. Schlicker A., Peschke P., Burkle A., et al. Four-amino-1,8-naphthalimide: A novel inhibitor of poly(ADP-ribose) polymerase and radiation sensitizer. Int J Radiat Biol 1999, 75:91-100.
17. Russo A.L., Kwon H.C., Burgan W.E., et al. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res 2009, 15:607-612.
18. Donawho C.K., Luo Y., Penning T.D., et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007, 13:2728-2737.
19. Noel G., Giocanti N., Fernet M., et al. Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery. BMC Cell Biol 2003, 4:7.
20. Schultz N., Lopez E., Saleh-Gohari N., et al. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res 2003, 31:4959-4964.
21. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
22. Gupta A., Yang Q., Pandita R.K., et al. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle 2009, 8:2198-2210.
23. Mendes-Pereira A.M., Martin S.A., Brough R., et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO. Mol Med 2009, 1:315-322.
24. Fan R., Kumaravel T.S., Jalali F., et al. Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. Cancer Res 2004, 64:8526-8533.
25. Ishkanian A.S., Mallof C.A., Ho J., et al. High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate 2009, 69:1091-1100.
26. Bristow R.G., Ozcelik H., Jalali F., et al. Homologous recombination and prostate cancer: A model for novel DNA repair targets and therapies. Radiother Oncol 2007, 83:220-230.
27. Dungey F.A., Caldecott K.W., Chalmers A.J. Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol Cancer Ther 2009, 8:2243-2254.
28. Bennardo N., Cheng A., Huang N., et al. Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet 2008, 4:e1000110.
29. Wang M., Wu W., Rosidi B., et al. PARP-1 and ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res 2006, 34:6170-6182.
30. Loser D.A., Shibata A., Shibata A.K., et al. Chalmers: Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther 2010, 9:1775-1787.
31. Martin S.A., Lord C.J., Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 2008, 18:80-86.
32. Bartkova J., Horejsi Z., Koed K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
33. Starcevic D., Dalal S., Sweasy J.B. Is there a link between DNA polymerase beta and cancer?. Cell Cycle 2004, 3:998-1001.
34. Hu Z., Ma H., Chen F., et al. XRCC1 polymorphisms and cancer risk: A meta-analysis of 38 case-control studies. Cancer Epidemiol Biomarkers Prev 2005, 14:1810-1818.
35. Bryant H.E., Helleday T. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Res 2006, 34:1685-1691.
36. Williamson C.T., Muzik H., Turhan A.G., et al. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther 2010, 9:347-357.
37. Lu H.R., Wang X., Wang Y. A stronger DNA damage-induced G2 checkpoint due to over-activated CHK1 in the absence of PARP-1. Cell Cycle 2006, 5:2364-2370.
38. Liu S.K., Olive P.L., Bristow R.G. Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials. Cancer Metastasis Rev 2008, 27:445-458.
39. Bhogal N., Jalali F., Bristow R.G. Microscopic imaging of DNA repair foci in irradiated normal tissues. Int J Radiat Biol 2009, 85:732-746.
40. Bhogal N., Kaspler P., Jalali F., et al. Late residual gamma-H2AX foci in murine skin are dose responsive and predict radiosensitivity in vivo. Radiat Res 2010, 173:1-9.
41. Cheng C.L., Johnson S.P., Keir S.T., et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 2005, 4:1364-1368.
42. Jones P., Altamura S., Boueres J., et al. Discovery of 2-{4-[(3S)-piperidine-3-yl] phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem 2009, 52:7170-7185.
43. Mason K.A., Valdecanas D., Hunter N.R., et al. INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin. Invest New Drugs 2008, 26:1-5.
44. Menear K.A., Adcock C., Boulter R., et al. Four-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phth alazin-1-one: A novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008, 51:6581-6591.
45. Albert J.M., Cao C., Kim K.W., et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007, 13:3033-3042.
46. Calabrese C.R., Almassy R., Barton S., et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004, 96:56-67.
47. Hay T., Matthews J.R., Pietzka L., et al. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous. Breast Cancer 2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 2009, 69:3850-3855.
48. Khan K., Araki K., Wang D., et al. Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427. Head Neck 2010, 381-391.
49. Ali M., Telfer B.A., McCrudden C., et al. Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: A contributory factor to chemopotentiation in vivo?. Clin Cancer Res 2009, 15:6106-6112.
50. Bindra R.S., Schaffer P.J., Meng A., et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol 2004, 24:8504-8518.
51. Bristow R.G., Hill R.P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008, 8:180-192.
52. Chan N., Koritzinsky M., Zhao H., et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 2008, 68:605-614.
53. Meng A.X., Jalali F., Cuddihy A., et al. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol 2005, 76:168-176.
54. Liu S.K., Coackley C., Krause M., et al. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol 2008, 88:258-268.
55. Choudhury A., Zhao H., Jalali F., et al. Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol Cancer Ther 2009, 8:203-213.